Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation
Your view on NYMXF
Overview
What the company does, where it operates, and who runs it.
About Nymox Pharmaceutical Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul Averback
- Headquarters
- Bay & Deveaux Streets, Nassau, BS
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul Averback
- Headquarters
- Bay & Deveaux Streets, Nassau, BS
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally.
Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nymox Pharmaceutical Corporation, and the rating behind it. NYMXF last traded at $0.05; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nymox Pharmaceutical Corporation. Starting points for Nymox Pharmaceutical Corporation: EPS -$0.04, beta 8.90 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nymox Pharmaceutical Corporation. Nymox Pharmaceutical Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nymox Pharmaceutical Corporation. Trailing twelve-month EPS for Nymox Pharmaceutical Corporation stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nymox Pharmaceutical Corporation. Nymox Pharmaceutical Corporation has reported as a listed company since 1997. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nymox Pharmaceutical Corporation valued side by side against its closest peers. Nymox Pharmaceutical Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nymox Pharmaceutical Corporation, and how their positions are changing. At a $4.8M market value, institutional positions materially move Nymox Pharmaceutical Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nymox Pharmaceutical Corporation executives and directors. Shares of Nymox Pharmaceutical Corporation have traded between $0.03 and $0.15 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nymox Pharmaceutical Corporation. Nymox Pharmaceutical Corporation is a $4.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nymox Pharmaceutical Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nymox Pharmaceutical Corporation. Coverage tracks Nymox Pharmaceutical Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.